drugset / Trial / NCT01521585
A Phase II Safety and Tolerability Study With SEN0014196
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The principal aim of this study is to obtain safety and tolerability data when SEN0014196 is administered orally over 12 weeks to male and female patients with Huntington's Disease.
Timeline
- Start
- 2011-11
- Primary completion
- 2012-10
- Completion
- 2012-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SEN0014196 | Unknown | 50 mg | Oral |
| Subject | SEN0014196 | Unknown | 200 mg | Oral |